Search results
-
Dou Group: Evaluación de Socios para el Garanti Bank
Khanna, Tarun; Palepu, Krishna G.; Bullock, Richard J.Case HBS-714S02Knowledge and CommunicationEn agosto de 2005, la dirección del Grupo Dogus de Turquía considera oportunidades para su empresa insignia, Garanti Bank, asociarse con una institución financiera extranjera. El caso describe el sector bancario turco y la posición de Garanti Bank dentro de ella, y le pide a los estudiantes a considerar si la asociación tiene sentido para Garanti y, si es así, qué licitador se debe seleccionar.Starting at €8.20
-
Innovación y negocios en mercados emergentes
Jones, Geoffrey G.; Khanna, Tarun; Wright, Nataliya Langburd; Spencer, MorganCase HBS-320S10Knowledge and CommunicationStarting at €8.20
-
HCL Technologies (A)
Hill, Linda A.; Khanna, Tarun; Stecker, Emily A.Case HBS-408004-EKnowledge and CommunicationThis case is accompanied by a Video Short that can be shown in class or included in a digital coursepack. Instructors should consider the timing of making the video available to students, as it may reveal key case details. When Vineet Nayar became president of HCL Technologies, a global IT services business, in April 2005, he knew the company needed drastic change. Since its founding as a hardware company in the 1970s, HCL had grown into an enter...Starting at €8.20
-
Impact Investment, Catalytic Capital and Blended Finance
Khanna, Tarun; Nanda, Ramana; Roth, Benjamin N.; Trelstad, BrianCase HBS-321078-EKnowledge and CommunicationStarting at €8.20
-
Genzyme's CSR Dilemma: How to Play its HAND
Bartlett, Christopher A.; Khanna, Tarun; Choudhury, PrithwirajCase HBS-910407-EKnowledge and CommunicationGenzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases, (e.g. malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should management decide to fund. But the bigger issue is how this program developed under the umbrella role Genzyme's corporate social responsibility fits into its global competitive strategy.Starting at €8.20